<DOC>
	<DOCNO>NCT00456833</DOCNO>
	<brief_summary>This study aim ass value combine treatment RAD001 erlotinib patient advance Non Small Cell Lung Cancer treat chemotherapy systemic therapy .</brief_summary>
	<brief_title>Combination RAD001 Erlotinib Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Age 18 year Advanced Non Small Cell Lung Cancer respond chemotherapy treatment include either cisplatin carboplatin Only 12 previous chemotherapy regimen advance disease More 2 week previous surgery , radiation chemotherapy Ability perform normal daily function Exclusion criterion : Chronic steroid treatment Prior treatment EGFR inhibitor Active bleed condition , skin condition , gastrointestinal disorder , mouth ulcer , eye condition severe medical condition Other cancer within past 2 year Pregnant breastfeeding woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Advanced lung cancer</keyword>
	<keyword>RAD</keyword>
	<keyword>RAD001</keyword>
	<keyword>erlotinib</keyword>
</DOC>